AIM Breakfasts

AIM BREAKFAST – 25th January 2017

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 972

Total number of AIM Companies trading: 950*
* As at 20 January 2017

Dish of the Day:

Jackpot Joy is due to join the Main Market today under the ticker JPJ.L

Off the Menu:

No AIM Leavers Today

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): 85*

Total number of ISDX Growth Market Companies trading: 81*
* As at 20 January 2017

Dish of the Day:

No NEX Growth Market Joiners Today

Off the Menu:

No NEX Growth Market Leavers Today

What’s Cooking in the IPO Kitchen?

Impact healthcare REIT— Intends to float on the main market. Seeks to raise £160m to acquire a portfolio of up to 58 care homes. Expected Admission 7 March.

Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas  exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise.

Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January 2017.

 

Breakfast Buffet

Fitbug Holdings* (FITB.L) 0.26p £3.26m

The digital wellness technology provider for corporate organisations, has successfully completed, subject only to Admission, a cash placing to raise gross proceeds of £1,000,000  at a subscription price of 0.2 pence per share.   The Company intends to use the funds raised from the Placing for general corporate purposes.  Fitbug CEO Anna Gudmundson said: “We are pleased to have raised these additional funds at this time. We have made good progress with the development and sales of our digital wellness programmes in pursuit of our service based strategy to focus on corporate wellness.  We believe that our prospects for 2017 are positive and we are now looking for opportunities to accelerate our growth strategy.”

 

Cambridge Cognition Holdings* (COG.L) 70.5p £14.4m

The neuroscience digital health Company  has received 510(k) clearance from the U.S. Food and Drug Administration to market its CANTAB Mobile product as a medical device in the U.S. Since being classified as a European Medical Device in 2013, CANTAB Mobile has been used routinely to assess over 26,000 patients in the UK who had concerns about their memory or were considered by their physician to be at increased risk of dementia. “Access to the large US healthcare market combined with the recent investment in our U.S. operation will help underpin the Company’s revenues and its continued growth.”

 

One Media iP Group (OMIP.L) 3.25p £2.31m

The digital media content provider which consolidates, exploits and monetises intellectual property rights around music and video, has renewed the exclusive rights to the MD Production music catalogue for recoupable advance of  $18,000. The MD catalogue comprises over 1,000 original recordings from the 1960s to the 1980s.  The tracks have been marketed exclusively by One Media since 2007 on a royalty-sharing basis. MD Productions has been a long-term music provider and has received three advances and on-going royalties from One Media throughout the term.  One Media is pleased to report that it has always fully recouped its advances throughout the relationship.

 

StatPro Group (SOG.L) 100p £64.71m

FYDec16 trading update from provider of cloud-based portfolio analysis and asset pricing services for the global asset management industry.  Group Annualised Recurring Revenue increased by 18% to £39.3m. Forward order book of contracted revenue up 9% to £46m. StatPro Revolution, the cloud-based portfolio analysis service, ARR increased by 68% to £15.0m. Net debt was £10.1m. “We have had a good year with the Group’s revenue and profitability remaining in line with our expectations. Notable highlights include two acquisitions, the launch of Revolution Performance in September 2016 and our best year yet for sales of StatPro Revolution.” FY17E PE of 28.8x and 2.8% yield.

 

Wynnstay Group (WYN.L) 557.5p £108.68m

FYOct16 results from the manufacturer and supplier of agricultural products to farmers and the wider rural community. Satisfactory results in line with market expectations despite tough trading environment. Group revenue of £368.14m (2015: £377.38m) – impacted by deflation.  Earnings per share of 30.01p (2015: 34.66p). Proposed final dividend of 8.00p – takes total for the year to 12.00p (11.10p), up 8.11%.  Trading environment showing signs of recovery with improving output prices for farmers. New financial year has started in line with management expectations

 

Immupharma (IMM.L) 46.5p £57.96m

The specialist drug discovery and development Company, has provided further details of patient participation following confirmation (as announced on 22 December 2016) that the Company had successfully completed, on target, patient recruitment into its pivotal 52-week Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. 200 patients successfully recruited and randomised (dosed). 7 Countries and 28 sites are participating in the study (US/Europe/Mauritius). No Serious Adverse Events reported to date. Top line results expected Q1 2018.

 

Beximco Pharmaceuticals (BXP.L) 57p £51.84m

The fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the creation of a joint venture  with BioCare Manufacturing (M) Sdn Bhd based in Malaysia, as the Company’s first overseas manufacturing collaboration. Under the terms of the JV, Beximco Pharma will provide full technical support to BioCare for the establishment of manufacturing facilities in Seri Iskandar Pharmaceutical Park, Perak, Malaysia to produce specialised pharmaceutical products. Beximco will be issued 30% of the equity shares in the JV company.  BioCare will operate and fund the facility. 1st sales expected this year although no material contribution expected in short term.

 

Clinigen (CLIN.L) 810p £932.26m

H1Dec16 trading update from the global pharmaceutical and services Company .  Gross profit up 34% driven by a combination of good organic growth across all divisions, a full six months contribution from Link Healthcare and currency benefits.  Excellent growth by Link Healthcare and Clinical Trial Services. Strong growth in Managed Access and Specialty Pharma. “We are trading in line with our expectations and are well positioned to deliver good performances across all divisions in H2.”  FYJun17E PE 19.6x and 0.6% yield.

 

Audioboom Group (BOOM.L) 2.75p £17.55m

The leading spoken word audio on-demand platform for hosting, distributing and monetising content, has entered into a conditional sale and purchase agreement to acquire the Neuro-linguistic Programming and Artificial Intelligence development Company, SONR. The consideration for the acquisition will be approximately £1.42m, to be satisfied by the issue of shares in Audioboom at an equivalent of 2.5p per share. A new £1m convertible loan note has been issued to support the working capital requirements of the combined Audioboom group and SONR businesses.

 

Minds + Machines Group (MMX.L) 9.38p £65.61m

FYDec16 trading update from owner and operator of Internet top-level domains. Topline billings growth of 100% for the year ended 31st December 2016. Total billings of $15.8m were achieved for FY 2016 compared to $7.9m for FY 2015, with the strong performance of H1 2016 continuing into H2 where billings were up 30% at $7.7m compared to the same period last year.  Operating expenditures cut by over 40% to approximately $6.8m. Operating EBITDA, before restructuring costs, as defined in the Interims, is expected to be over $3.5m for the full year ended 31 December 2016, compared to a $12.1m loss.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.